| Assessment Status | Awaiting HTA submission from Applicant |
| HTA ID | 22044 |
| Drug | Tisagenlecleucel |
| Brand | Kymriah® |
| Indication | For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 28/06/2022 |
| Rapid review completed | 27/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 31/08/2022 |
| Pre-submission consultation with Applicant | 06/12/2022 |
